<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520894</url>
  </required_header>
  <id_info>
    <org_study_id>ROCK</org_study_id>
    <nct_id>NCT03520894</nct_id>
  </id_info>
  <brief_title>Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer</brief_title>
  <acronym>ROCK</acronym>
  <official_title>Radiotherapy in Preoperative Setting With CyberKnife as Treatment in Early Breast Cancer: an Explorative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria Careggi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria Careggi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to prospectively evaluate, in patients affected by early breast
      cancer, safety and feasibility of single fraction radiotherapy with Cyberknife R in
      preoperative setting, and to identify factors predictive for outcome based on biologic and
      clinical parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monocentric, open-label, single-arm phase II study evaluating safety and efficacy of
      neoadjuvant radiotherapy in early breast cancer patients. Patients eligible are women aged 50
      or more years old, affected by histologically proven invasive breast cancer, with positive
      hormonal receptors, grading 1 or 2, HER-2 negative, without lymphovascular invasion, and
      tumour size up to 2 cm (measured on mammography, ultrasound or magnetic resonance), negative
      clinical nodal status, eligible for BCS.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of acute skin toxicity events, measured according to RTOG/EORTC scale</measure>
    <time_frame>15 days</time_frame>
    <description>Acute skin toxicity (from the end of radiotherapy to surgery) according to Radiation Therapy Oncology Group (RTOG)/ European Organization for research and treatment of cancer (EORTC) scale. Measuring acute skin toxicity from a minimum of 0 (no change over baseline) to a maximum of 4 (Ulceration, Hemorrage, necrosis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with pathologic complete response (pCR) after surgery,according to Chevalier score</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of pCR according to Chevalier score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with complete resection after surgical excision</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of complete resection R0 with margin&lt;1cm (except for deep margin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients free from locoregional progression at 36 months</measure>
    <time_frame>36 months</time_frame>
    <description>locoregional progression free survival measured at 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients free from metastatic progression at 36 months</measure>
    <time_frame>36 months</time_frame>
    <description>Metastasis progression free survival measured at 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients dying for breast cancer at 36 months</measure>
    <time_frame>36 months</time_frame>
    <description>cause-specific free survival measured at 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients dying for any cause at 36 months</measure>
    <time_frame>36 months</time_frame>
    <description>global survival measured at 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of chronic skin toxicity events, measured according to CTCAE</measure>
    <time_frame>90 days</time_frame>
    <description>Incidence of chronic skin toxicity (over 90 days since the end of radiotherapy; fibrosis, telangiectasia, tardive oedema) according to Common terminology criteria for adverse events (CTCAE) v 4.03. From a minimum of 1 (Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated
to a maximum of 4 (Life-threatening consequences; urgent intervention indicated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of chronic extra-cutaneous toxicity, measured according to CTCAE</measure>
    <time_frame>90 days</time_frame>
    <description>Incidence of chronic extra-skin toxicity (over 90 days from the end of radiotherapy; lung fibrosis, pericarditis, myocardial ischemia, valvulopathy, thoracic wall pain, fracture) according to according to Common terminology criteria for adverse events (CTCAE) v 4.03. From a minimum of 1 (Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated
to a maximum of 4 (Life-threatening consequences; urgent intervention indicated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of differential genetic expression, immunologic and histopathologic features of tumor sample and biomarkers in blood and urine samples with toxicity and rate of response to radiotheraèy</measure>
    <time_frame>60 days</time_frame>
    <description>Radiogenomic: confirm of differential genetic expression of genes already validated in previous literature (30-Radiation- induced gene signature; AOI 16-gene breast signature; IRDS gene signature) with Next Generation Sequencing (NGS, RNA-seq) or Real Time PCR on frozen biopsy tissue.
Immunologic: quantitative analysis of infiltrating leucocytes (MS and M1 macrophages, CD8+ and CD4+ lymphocytes) with immunohistochemistry on fresh biopsy tissue Histopathologic: qualitative analyses (pericytes) and quantitative pattern of vascularization in immunohistochemistry.
Biochemical: analysis of oxidative stress markers on peripheral blood and urines:
a) 1 hour before SBRT; b) 1 hour after SBRT; c) 1 week after SBRT; d) during 24 hours before BCS; e) during 2-4 weeks after BCS.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Early Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant radiotherapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early breast cancer patients eligible for breast conservative surgery will undergo neoadjuvant radiotherapy with Cyberknife robotic system</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Neoadjuvant radiotherapy</intervention_name>
    <description>single 21 Gy fraction of Radiotherapy before surgery</description>
    <arm_group_label>Neoadjuvant radiotherapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Women ≥ 50 years old

          3. Histological diagnosis of invasive breast cancer

          4. ER positive (≥ 10% of tumoral cells present ER) and/or PR positive (≥ 10% of tumoral
             cells present PR)

          5. Grading 1 or 2

          6. Her2 negative (IHC 0-1+; in patients with IHC 2+, absence of amplification at FISH

          7. No lymphovascular invasion evidence at biopsy

          8. Early breast cancer (T1 N0 M0) clinically and radiologically defined (ultrasound
             study/ magnetic resonance)

          9. Patients eligible for BCS.

        Exclusion Criteria:

        Extension of breast disease within 5 mm from the skin surface 2. Tumor size &amp;gt; 2 cm 3.
        Patients affected by collagenopathies 4. Patients with BRCA1/2 mutations 5. Previous
        irradiation to homolateral breast 6. Previous irradiation to homolateral thoracic wall 7.
        DCIS and/or Paget's disease 8. Psychiatric disorders preventing informed consent signature.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002 Oct 17;347(16):1227-32.</citation>
    <PMID>12393819</PMID>
  </results_reference>
  <results_reference>
    <citation>Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 Oct 17;347(16):1233-41.</citation>
    <PMID>12393820</PMID>
  </results_reference>
  <results_reference>
    <citation>Meattini I, Guenzi M, Fozza A, Vidali C, Rovea P, Meacci F, Livi L. Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer. Breast Cancer. 2017 Jan;24(1):52-62. doi: 10.1007/s12282-016-0694-3. Epub 2016 Mar 30. Review.</citation>
    <PMID>27025498</PMID>
  </results_reference>
  <results_reference>
    <citation>Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011 Nov 12;378(9804):1707-16. doi: 10.1016/S0140-6736(11)61629-2. Epub 2011 Oct 19. Review.</citation>
    <PMID>22019144</PMID>
  </results_reference>
  <results_reference>
    <citation>Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabár L, Nordgren H, Adami HO. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol. 1999 Aug;17(8):2326-33.</citation>
    <PMID>10561294</PMID>
  </results_reference>
  <results_reference>
    <citation>Arriagada R, Lê MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol. 1996 May;14(5):1558-64.</citation>
    <PMID>8622072</PMID>
  </results_reference>
  <results_reference>
    <citation>Jameel JK, Rao VS, Cawkwell L, Drew PJ. Radioresistance in carcinoma of the breast. Breast. 2004 Dec;13(6):452-60. Review.</citation>
    <PMID>15563851</PMID>
  </results_reference>
  <results_reference>
    <citation>Vicini FA, Baglan KL, Kestin LL, Mitchell C, Chen PY, Frazier RC, Edmundson G, Goldstein NS, Benitez P, Huang RR, Martinez A. Accelerated treatment of breast cancer. J Clin Oncol. 2001 Apr 1;19(7):1993-2001. Review.</citation>
    <PMID>11283132</PMID>
  </results_reference>
  <results_reference>
    <citation>Greenup RA, Camp MS, Taghian AG, Buckley J, Coopey SB, Gadd M, Hughes K, Specht M, Smith BL. Cost comparison of radiation treatment options after lumpectomy for breast cancer. Ann Surg Oncol. 2012 Oct;19(10):3275-81. doi: 10.1245/s10434-012-2546-5. Epub 2012 Aug 1.</citation>
    <PMID>22851048</PMID>
  </results_reference>
  <results_reference>
    <citation>Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, Luini A, Veronesi P, Galimberti V, Zurrida S, Leonardi MC, Lazzari R, Cattani F, Gentilini O, Intra M, Caldarella P, Ballardini B. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013 Dec;14(13):1269-77. doi: 10.1016/S1470-2045(13)70497-2. Epub 2013 Nov 11.</citation>
    <PMID>24225155</PMID>
  </results_reference>
  <results_reference>
    <citation>Bensaleh S, Bezak E, Borg M. Review of MammoSite brachytherapy: advantages, disadvantages and clinical outcomes. Acta Oncol. 2009;48(4):487-94. doi: 10.1080/02841860802537916. Review.</citation>
    <PMID>19031175</PMID>
  </results_reference>
  <results_reference>
    <citation>Mukesh MB, Barnett GC, Wilkinson JS, Moody AM, Wilson C, Dorling L, Chan Wah Hak C, Qian W, Twyman N, Burnet NG, Wishart GC, Coles CE. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol. 2013 Dec 20;31(36):4488-95. doi: 10.1200/JCO.2013.49.7842. Epub 2013 Sep 16.</citation>
    <PMID>24043742</PMID>
  </results_reference>
  <results_reference>
    <citation>Klepczyk LC, Keene KS, De Los Santos JF. Accelerated partial breast irradiation for early-stage breast cancer: controversies and current indications for use. Curr Treat Options Oncol. 2013 Mar;14(1):51-65. doi: 10.1007/s11864-012-0213-5. Review.</citation>
    <PMID>23179757</PMID>
  </results_reference>
  <results_reference>
    <citation>Verma V, Simone CB 2nd, Zhen W. Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer. Oncologist. 2016 Feb;21(2):131-3. doi: 10.1634/theoncologist.2015-0348. Epub 2016 Jan 13.</citation>
    <PMID>26764248</PMID>
  </results_reference>
  <results_reference>
    <citation>Goggin LM, Descovich M, McGuinness C, Shiao S, Pouliot J, Park C. Dosimetric Comparison Between 3-Dimensional Conformal and Robotic SBRT Treatment Plans for Accelerated Partial Breast Radiotherapy. Technol Cancer Res Treat. 2016 Jun;15(3):437-45. doi: 10.1177/1533034615601280. Epub 2015 Sep 2.</citation>
    <PMID>26335703</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu Q, Chen Y, Grimm J, Fan J, An L, Xue J, Pahlajani N, Lacouture T. Dosimetric investigation of accelerated partial breast irradiation (APBI) using CyberKnife. Med Phys. 2012 Nov;39(11):6621-8. doi: 10.1118/1.4757616.</citation>
    <PMID>23127056</PMID>
  </results_reference>
  <results_reference>
    <citation>Obayomi-Davies O, Kole TP, Oppong B, Rudra S, Makariou EV, Campbell LD, Anjum HM, Collins SP, Unger K, Willey S, Tousimis E, Collins BT. Stereotactic Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer: Rationale, Feasibility, and Early Experience Using the CyberKnife Radiosurgery Delivery Platform. Front Oncol. 2016 May 23;6:129. doi: 10.3389/fonc.2016.00129. eCollection 2016.</citation>
    <PMID>27242967</PMID>
  </results_reference>
  <results_reference>
    <citation>Tian H, Gao Z, Li H, Zhang B, Wang G, Zhang Q, Pei D, Zheng J. DNA damage response--a double-edged sword in cancer prevention and cancer therapy. Cancer Lett. 2015 Mar 1;358(1):8-16. doi: 10.1016/j.canlet.2014.12.038. Epub 2014 Dec 17. Review.</citation>
    <PMID>25528631</PMID>
  </results_reference>
  <results_reference>
    <citation>Dayal R, Singh A, Pandey A, Mishra KP. Reactive oxygen species as mediator of tumor radiosensitivity. J Cancer Res Ther. 2014 Oct-Dec;10(4):811-8. doi: 10.4103/0973-1482.146073. Review.</citation>
    <PMID>25579513</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003 May 16;300(5622):1155-9.</citation>
    <PMID>12750523</PMID>
  </results_reference>
  <results_reference>
    <citation>Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012 Mar;177(3):311-27. Epub 2012 Jan 9. Review.</citation>
    <PMID>22229487</PMID>
  </results_reference>
  <results_reference>
    <citation>Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006 May 15;203(5):1259-71. Epub 2006 Apr 24.</citation>
    <PMID>16636135</PMID>
  </results_reference>
  <results_reference>
    <citation>Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72. doi: 10.1146/annurev-immunol-032712-100008. Epub 2012 Nov 12. Review.</citation>
    <PMID>23157435</PMID>
  </results_reference>
  <results_reference>
    <citation>Milas L. Tumor bed effect in murine tumors: relationship to tumor take and tumor macrophage content. Radiat Res. 1990 Aug;123(2):232-6.</citation>
    <PMID>2389010</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim KS, Shin KH, Choi N, Lee SW. Hypofractionated whole breast irradiation: new standard in early breast cancer after breast-conserving surgery. Radiat Oncol J. 2016 Jun;34(2):81-7. doi: 10.3857/roj.2016.01697. Epub 2016 Jun 17. Review.</citation>
    <PMID>27306774</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee EJ, Kim JW, Yoo H, Kwak W, Choi WH, Cho S, Choi YJ, Lee YJ, Cho J. Single high-dose irradiation aggravates eosinophil-mediated fibrosis through IL-33 secreted from impaired vessels in the skin compared to fractionated irradiation. Biochem Biophys Res Commun. 2015 Aug 14;464(1):20-6. doi: 10.1016/j.bbrc.2015.05.081. Epub 2015 Jun 3.</citation>
    <PMID>26047701</PMID>
  </results_reference>
  <results_reference>
    <citation>Davis AM, O'Sullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, Chabot P, Hammond A, Benk V, Isler M, Freeman C, Goddard K, Bezjak A, Kandel RA, Sadura A, Day A, James K, Tu D, Pater J, Zee B. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol. 2002 Nov 15;20(22):4472-7.</citation>
    <PMID>12431971</PMID>
  </results_reference>
  <results_reference>
    <citation>Grimsby GM, Gray R, Dueck A, Carpenter S, Stucky CC, Aspey H, Giurescu ME, Pockaj B. Is there concordance of invasive breast cancer pathologic tumor size with magnetic resonance imaging? Am J Surg. 2009 Oct;198(4):500-4. doi: 10.1016/j.amjsurg.2009.07.012.</citation>
    <PMID>19800455</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenstein BS, Lymberis SC, Formenti SC. Biologic comparison of partial breast irradiation protocols. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1393-404.</citation>
    <PMID>15590170</PMID>
  </results_reference>
  <results_reference>
    <citation>Veronesi U, Orecchia R, Luini A, Galimberti V, Gatti G, Intra M, Veronesi P, Leonardi MC, Ciocca M, Lazzari R, Caldarella P, Simsek S, Silva LS, Sances D. Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery: experience with 590 cases. Ann Surg. 2005 Jul;242(1):101-6.</citation>
    <PMID>15973107</PMID>
  </results_reference>
  <results_reference>
    <citation>Fukutomi T, Yamamoto H, Nanasawa T, Tsukiyama I, Ogino H, Itabashi M, Hirota T. [Histological and biological evaluation of preoperative radiotherapy on T1N0 breast carcinoma]. Nihon Geka Gakkai Zasshi. 1992 Feb;93(2):183-8. Japanese.</citation>
    <PMID>1348103</PMID>
  </results_reference>
  <results_reference>
    <citation>Kambach DM, Sodi VL, Lelkes PI, Azizkhan-Clifford J, Reginato MJ. ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation. Oncogene. 2014 Jan 30;33(5):589-98. doi: 10.1038/onc.2012.629. Epub 2013 Jan 14.</citation>
    <PMID>23318431</PMID>
  </results_reference>
  <results_reference>
    <citation>Horton JK, Blitzblau RC, Yoo S, Geradts J, Chang Z, Baker JA, Georgiade GS, Chen W, Siamakpour-Reihani S, Wang C, Broadwater G, Groth J, Palta M, Dewhirst M, Barry WT, Duffy EA, Chi JT, Hwang ES. Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers. Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):846-55. doi: 10.1016/j.ijrobp.2015.03.007. Epub 2015 Mar 14.</citation>
    <PMID>26104938</PMID>
  </results_reference>
  <results_reference>
    <citation>Oh DS, Cheang MC, Fan C, Perou CM. Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. Radiat Res. 2014 Feb;181(2):193-207. doi: 10.1667/RR13485.1. Epub 2014 Feb 14.</citation>
    <PMID>24527691</PMID>
  </results_reference>
  <results_reference>
    <citation>Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, Roizman B, Bergh J, Pawitan Y, van de Vijver MJ, Minn AJ. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18490-5. doi: 10.1073/pnas.0809242105. Epub 2008 Nov 10.</citation>
    <PMID>19001271</PMID>
  </results_reference>
  <results_reference>
    <citation>Rotblat B, Grunewald TG, Leprivier G, Melino G, Knight RA. Anti-oxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers. Oncotarget. 2013 Dec;4(12):2577-90.</citation>
    <PMID>24342878</PMID>
  </results_reference>
  <results_reference>
    <citation>Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, Paiar F, Scotti V, De Luca Cardillo C, Bastiani P, Orzalesi L, Casella D, Sanchez L, Nori J, Fambrini M, Bianchi S. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015 Mar;51(4):451-63. doi: 10.1016/j.ejca.2014.12.013. Epub 2015 Jan 17.</citation>
    <PMID>25605582</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>April 28, 2018</last_update_submitted>
  <last_update_submitted_qc>April 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria Careggi</investigator_affiliation>
    <investigator_full_name>Lorenzo Livi</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

